The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $132.
PulteGroup
PHM · a US exchange · USD · Market cap $24.7B · 6,506 employees
PulteGroup, Inc., through its subsidiaries, engages in the homebuilding business in the United States.
PASS · Titan Ethical · score 91.1Price as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price122.52 USD at the 19 Nov 2026 close
- Our value readFair vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 17 Nov 2026
- Ethical screenPasses, score 91.1 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.64)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $90.00 to $126.89, base estimate $110.34 (screen dated 2026-11-19).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.64, read 2026-11-19
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
PulteGroup holds its Markup at $122.52. The statistical read favours the sellers, held for 14 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 14 days |
| Price at the screen | $122.52 |
| Valuation | 13.84 trailing · 13.76 forward price to earnings |
| Values screen | PASS · score 91.1 |
| Beta | 1.18 |
Five Screens: PHM's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 12.73% | Below 33% | Pass |
| Interest-bearing cash | 0.93% | Below 33% | Pass |
| Receivables | 12.37% | Below 49% | Pass |
| Revenue purity | 0.26% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
PulteGroup clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PHM's ethical verdict changes
Today PHM passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 19 Nov 2026: it trades above our $110.34 fair value estimate, moderate competitive moat.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. The price runs 11.0% above the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $110.34, with a range of $90.00 to $126.89, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Forward P/E | 13.8xreasonably valued |
| Trailing P/E | 13.8xreasonably valued |
| EPS, trailing | 9.36 |
| EPS, forward | 9.41 |
| Revenue growth | -9.8%revenue is shrinking |
| Profit margin | 11.2%thin but positive margins |
| Return on equity | 13.9%a solid return on shareholder capital |
| FCF yield | 3.42% |
| Dividend yield | 0.83% |
| Debt to equity | 0.18minimal debt: a conservative balance sheet |
| Current ratio | 6.99comfortably covers its short-term bills |
| Beta | 1.18moves a little more than the market |
| Short interest, float | 0.06% |
| 52-week range | 107.16 - 144.50 |
| Moat | MODERATE |
| Market cap | $24.7B |
| Employees | 6,506 |
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $132.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $132.
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.4% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $133.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $135. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $135. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $135. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $136. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $136. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (17 analysts) rates it buy, with a mean price target of $136. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Existing-Home Sales Fall to Lowest Level Since 2010 as Mortgage Rates Take Their Toll Yahoo Finance · 8d ago
- What Sent Lennar Stock Lower On Tuesday? Yahoo Finance · 9d ago
- Construction Underway on Del Webb at Chatham Park, New Home Details Revealed Yahoo Finance · 10d ago
- Beyond Sunshine: New PulteGroup Survey Highlights What Matters Most to Homebuyers in Their Next Chapter Yahoo Finance · 10d ago
- 2026 GeorgiaCMO ORBIE Awards Celebrate Top Marketing Executives Yahoo Finance · 11d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-08 | SNYDER LILA | Director | 3,339 | $391,264 | |
| 2026-04-29 | GRISE CHERYL W | Director | 1,507 | · | |
| 2026-04-29 | BLAIR BRYCE | Director | 1,507 | · | |
| 2026-04-29 | HAWAUX ANDRE J | Director | 1,507 | · | |
| 2026-04-29 | ACTIS-GRANDE KRISTEN | Director | 1,507 | · | |
| 2026-04-29 | SCHALL BENJAMIN | Director | 1,507 | · | |
| 2026-04-29 | GANNON KRISTIN F | Director | 1,507 | · | |
| 2026-04-29 | SNYDER LILA | Director | 1,507 | · | |
| 2026-02-24 | HENRY KEVIN A | Officer | 5,173 | $729,574 | |
| 2026-02-10 | GANNON KRISTIN F | Director | 292 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-11 | Ro Khanna | Democrat | buy | 15K–50K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 15K–50K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 15K–50K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $110.90 | +12.7% | · | $1,127 | +12.7% |
| 2 months | $117.26 | +6.6% | · | $1,066 | +6.6% |
| 3 months | $127.39 | -1.9% | $0.26 | $983 | -1.7% |
| 6 months | $115.93 | +7.8% | $0.52 | $1,083 | +8.3% |
| 1 year | $112.53 | +11.1% | $1.04 | $1,120 | +12.0% |
| 2 years | $126.49 | -1.2% | $1.92 | $1,003 | +0.3% |
| 3 years | $86.28 | +44.9% | $2.72 | $1,480 | +48.0% |
| 5 years | $49.85 | +150.8% | $3.96 | $2,587 | +158.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PHM does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.